Show simple item record

Genetic Understanding of Stroke Treatment: Potential Role for Phosphodiesterase Inhibitors

dc.contributor.authorMunshi, Anjana
dc.contributor.authorDas, Satrupa
dc.date.accessioned2018-07-14T01:18:47Z
dc.date.available2018-07-14T01:18:47Z
dc.date.issued2017
dc.identifier.citationMunshi, A., & Das, S. (2017) Genetic Understanding of Stroke Treatment: Potential Role for Phosphodiesterase Inhibitors. Vol. 17. Advances in Neurobiology (pp. 445-461).en_US
dc.identifier.isbnPrint- 978-3-319-58809-4
dc.identifier.isbnOnline- 978-3-319-58811-7
dc.identifier.issn21905215
dc.identifier.urihttp://kr.cup.edu.in/handle/32116/1339
dc.description.abstractPhosphodiesterase (PDE) gene family is a large family having at least 21 genes and multiple versions (isoforms) of the phosphodiesterase enzymes. These enzymes catalyze the inactivation of intracellular mediators of signal transduction such as cAMP and cGMP and therefore, play a pivotal role in various cellular functions. PDE inhibitors (PDEI) are drugs that block one or more of the five subtypes of the PDE family and thereby prevent inactivation of the intracellular cAMP and cGMP by the respective PDE-subtypes. The first clinical use of PDEI was reported almost three decades ago. Studies later found the ability of these compounds to increase the levels of ubiquitous secondary messenger molecules that can cause changes in vascular tone, cardiac function and other cellular events and thus these findings paved the way for their use in various medical emergencies. PDEs are found to be distributed in many tissues including brain. Therefore, new therapeutic agents in the form of PDEI are being explored in neurodegenerative diseases including stroke. Although studies have revealed their use in cerebral infarction prevention, their full-fledged application in times of neurological emergency or stroke in specific has been very limited so far. Nevertheless, recent investigations suggest PDE4 and PDE5 inhibitors to play a vital role in mitigating stroke symptoms by modulating signaling mechanisms in PDE pathway. Further, extensive research in terms of their pharmacological properties like dosing, drug specific activities, use of simultaneous medications, ancillary properties of these compounds and studies on adverse drug reactions needs to be carried out to set them as standard drugs of use in stroke. ? Springer International Publishing AG 2017.en_US
dc.language.isoenen_US
dc.publisherSpringer New York LLCen_US
dc.subjectacetylsalicylic aciden_US
dc.subjectanagrelideen_US
dc.subjectanticoagulant agenten_US
dc.subjectcilostazolen_US
dc.subjectcyclic AMP phosphodiesteraseen_US
dc.subjectcyclic GMPen_US
dc.subjectdenbufyllineen_US
dc.subjectdipyridamoleen_US
dc.subjectenzyme inhibitoren_US
dc.subjectmilrinoneen_US
dc.subjectphosphodiesterase inhibitoren_US
dc.subjectrolipramen_US
dc.subjectsildenafilen_US
dc.subjecttadalafilen_US
dc.subjectvardenafilen_US
dc.subjectzaprinasten_US
dc.subjectphosphodiesteraseen_US
dc.subjectphosphodiesterase inhibitoren_US
dc.subjectphosphodiesterase IV inhibitoren_US
dc.subjectphosphodiesterase V inhibitoren_US
dc.subjectblood vessel toneen_US
dc.subjectbrain blood flowen_US
dc.subjectbrain cortexen_US
dc.subjectbrain infarctionen_US
dc.subjectcerebrovascular accidenten_US
dc.subjectdual antiplatelet therapyen_US
dc.subjectheart functionen_US
dc.titleGenetic Understanding of Stroke Treatment: Potential Role for Phosphodiesterase Inhibitorsen_US
dc.typeBook Chapteren_US
dc.identifier.doi10.1007/978-3-319-58811-7_16
dc.identifier.urlhttps://link.springer.com/chapter/10.1007%2F978-3-319-58811-7_16
dc.title.journalAdvances in Neurobiology


Files in this item

Thumbnail
Name:
27.pdf
Size:
414.9Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record